The study reported that administration of decitabine in combination with temozolomide re-sensitizes CM patients to temozolomide by dual modulation of DNA repair machinery due to depletion of DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT) and subsequent induction of DNA mismatch repair (MMR) pathway in temozolomide-refractory melanoma cells [244]. Here, MGMT is linked to melanoma.